<SEC-DOCUMENT>0001171843-20-005816.txt : 20200811
<SEC-HEADER>0001171843-20-005816.hdr.sgml : 20200811
<ACCEPTANCE-DATETIME>20200811151338
ACCESSION NUMBER:		0001171843-20-005816
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200811
FILED AS OF DATE:		20200811
DATE AS OF CHANGE:		20200811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		201092195

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_081120.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong>Date of report:&#160;</strong><strong>For the month of August 2020</strong></p><p style="text-align: center;"><strong>Commission File Number: 001-39084</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Innate Pharma S.A.</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>Innate Pharma S.A.<br />117 Avenue de Luminy&#8212;BP 30191<br />13009 Marseille, France <br />+ 33 (0) 4 30 30 30 &#160;</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p>Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </p><hr style="page-break-after: always;" noshade="noshade" /><p>
 <p align="center"><font style="font-size:10pt;"><strong>EXHIBIT INDEX</strong></font></p>   <p align="center" style="text-align: center;"><font style="font-size:10pt;">&#160;</font></p>  <table style="border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><strong><u>Exhibit</u></strong></font></td><td class="hugin"><font style="font-size:10pt;">&#160; &#160;</font></td><td style="vertical-align: bottom ; "><font style="font-size:10pt;"><strong><u>Description</u></strong></font></td></tr><tr><td class="hugin">&#160;</td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td></tr><tr><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">99.1</a></font></font></td><td class="hugin"><font style="font-size:10pt;">&#160;</font></td><td class="hugin"><font style="font-size:10pt;"><font style="font-size:10pt;"><a href="exh_991.htm" rel="nofollow">Press Release dated August 11, 2020</a></font> </font></td></tr></table></p><p /><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td>&#160;</td><td>&#160;</td><td style="text-transform: uppercase;" colspan="2"><strong>Innate Pharma S.A.</strong></td></tr><tr valign="top"><td style="width: 47%;">&#160;</td><td style="width: 6%;">&#160;</td><td style="text-align: center; width: 10%;">&#160;</td><td style="text-align: center; width: 84%;">&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr><tr valign="top"><td>Date: August 11, 2020</td><td>&#160;</td><td>By:</td><td style="border-bottom: black 1pt solid;">/s/ Laure-H&#233;l&#232;ne Mercier&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Name:&#160;&#160;&#160;&#160;&#160;</td><td>Laure-H&#233;l&#232;ne Mercier</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td>Title:</td><td>Chief Financial Officer</td></tr><tr valign="top"><td>&#160;</td><td>&#160;</td><td colspan="2"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Innate Pharma Obtains &#8364;6.8M in Public Funding for Its COVID-19 Research And Development Activities</strong></font></p><p style="text-align: center;"><strong></strong></p><p>
 <p align="justify">MARSEILLE, France, Aug.  11, 2020  (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH &#8211; ISIN: FR0010331421; Nasdaq: IPHA) (&#8220;<strong>Innate</strong>&#8221; or the <strong>&#8220;Company</strong>&#8221;) today announced the Company has obtained funding of &#8364;6.8M under the PSPC-COVID call for projects to support the Company&#8217;s COVID-19 research and development activities. This initiative is operated on behalf of the State by Bpifrance as part of the <em>Programme d&#8217;investissements d&#8217;avenir (PIA)</em>, led by the <em>Secr&#233;tariat g&#233;n&#233;ral pour l&#8217;investissement (SGPI)</em>.&#160;<br ></p>  <p align="justify">PSPC-COVID is a program established by the French government at the beginning of the pandemic to support the development of therapeutic solutions with a preventative or curative aim for COVID-19. Its objective is to finance research and development work, including Phase I or Phase II clinical trials carried out with French academic partners. &#160;</p>  <p align="justify">This funding will enable the Company to cover the development of its current COVID-19 activities which began in March 2020, including the EXPLORE COVID-19 translational research study and its two Phase II clinical trials, FORCE and ImmunONCOVID-20.</p>  <p align="justify">As part of this agreement with Bpifrance, the funding will be received in four consecutive tranches. The first tranche of &#8364;1.7M was received at signing, and the three remaining tranches will be received upon achievement of certain clinical milestones, particularly around the FORCE Phase II trial.&#160;</p>  <p align="justify">Each tranche is structured as follows: 20% as a non-reimbursable grant and 80% as an advance reimbursable only upon technical and commercial success.</p>  <p align="justify"><em>&#8220;We are pleased to have been selected for this funding by the French government in this effort to improve the prognosis of COVID-19 patients,&#8221; </em>said <strong>Laure-H&#233;l&#232;ne Mercier, Chief Financial Officer at Innate Pharma</strong>. <em>&#8220;Through this government initiative, we are able to contribute to an area of high medical need, in partnership with the H&#244;pitaux Universitaires de Marseille &#8211; AP&#8209;HM and the Centre L&#233;on B&#233;rard, while managing the financial considerations of high-risk research as the dynamic of the pandemic continues to evolve in France.</em>&#8221;&#160; <em>&#160;&#160;</em></p>  <p align="justify"><strong><strong>About Innate Pharma COVID-19 R&amp;D Activities</strong><sup>*</sup></strong></p>  <p align="justify">Innate has partnered with several France-based hospitals and academic centers to conduct three research and development programs:</p>  <p align="justify"><strong><strong>EXPLORE COVID-19: </strong></strong>This exploratory translational study, in collaboration with La Timone, North and&#160;Laveran hospitals and the Marseille Immunop&#244;le/AP-HM immunoprofiling laboratory at La Timone hospital, Marseille, analyzed the immune response of COVID-19 patients at varying stages of disease and found that patients who progress towards severe COVID-19 disease exhibit an activation of the C5a/C5aR1 pathway. Study results were published in <em><u>Nature</u></em> on July 29, 2020.</p>  <p align="justify"><strong><strong>FORCE (FOR C</strong></strong>OVID-19<strong><strong> E</strong></strong>limination<strong><strong>):</strong> </strong>Based on the findings from EXPLORE COVID-19, the Company launched the FORCE trial, sponsored by the H&#244;pitaux Universitaires de Marseille &#8211; AP&#8209;HM). The primary objective of this Phase II trial is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome.</p>  <p align="justify"><strong><strong>ImmunONCOVID-20:</strong> </strong>This controlled, randomized, study, sponsored by the Centre L&#233;on B&#233;rard, Lyon, is exploring monalizumab, a potentially first-in-class immune checkpoint inhibitor, and avdoralimab, amongst other treatment arms, to investigate the potential efficacy against COVID&#8209;19 in cancer patients with mild symptoms and pneumonia respectively.&#160;</p>  <p align="justify">Visit the <u>Company&#8217;s website</u> for more information on Innate&#8217;s COVID-19 efforts.</p>  <p align="justify"><strong><strong>About Innate Pharma:</strong></strong></p>  <p align="justify">Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.</p>  <p align="justify">Innate Pharma&#8217;s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma&#8217;s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.</p>  <p align="justify">Innate Pharma has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.</p>  <p align="justify">___________________________<br ><sup>*</sup>&#160;<em>This project has been supported by the State, under the Investing for the Future Program, operated by Bpifrance, the French national investment bank&#160;</em></p>  <p align="justify">Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.</p>  <p align="justify">Learn more about Innate Pharma at <u>www.innate-pharma.com </u></p>  <p align="justify"><strong><strong>Information about Innate Pharma shares:</strong></strong></p> <table align="center" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:15%; width:15%; min-width:15%;;text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>ISIN code</strong><br ><strong>Ticker code</strong><br ><strong>LEI</strong></td><td style="max-width:85%; width:85%; min-width:85%;;text-align: left ;  vertical-align: middle; vertical-align: top ; ">FR0010331421<br >Euronext: IPH Nasdaq: IPHA<br >9695002Y8420ZB8HJE29</td></tr></table> <p align="justify"><strong><strong>About Bpifrance:</strong></strong></p>  <p align="justify">Bpifrance is the French national investment bank. It finances businesses &#8211; at every stage of their development &#8211; through loans, guarantees, equity investments and export insurances. Bpifrance also provides extrafinancial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export&#133;).</p>  <p align="justify">More information on: www.bpifrance.fr/presse.bpifrance.fr. Follow Bpifrance on Twitter: @Bpifrance - @BpifrancePresse</p>  <p align="justify"><strong><strong>About the <em>Programme d&#8217;investissements d&#8217;avenir</em></strong></strong></p>  <p align="justify">With 57 billion euros, the <em>Programme d&#8217;investissements d&#8217;avenir (PIA)</em>, led by the <em>Secr&#233;tariat g&#233;n&#233;ral pour l&#8217;investissement (SGPI)</em>, was set up by the State to finance innovative and promising investments in the region, to enable France to increase its growth and employment potential. Part of this forward-looking investment program, endowed with &#8364;10 billion, is part of the &#8364;57 billion <em>Grand Plan d&#8217;Investissement (GPI)</em> newly launched by the Government in 2017 and carried out over the next five years to support structural reforms and meet four major challenges facing France: carbon neutrality, access to employment, competitiveness through innovation and the digital State.</p>  <p align="left">More information on: <u>https://www.gouvernement.fr/le-secretariat-general-pour-l-investissement</u>.&#160; Follow SGPI on Twitter: <u>@SGPI_avenir</u><u>.</u></p>  <p align="justify"><strong><strong>Disclaimer on forward-looking information and risk factors:</strong></strong></p>  <p align="justify">This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and similar expressions, is intended to identify forward-looking statements.&#160;Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts, the Company&#8217;s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company&#8217;s business, financial condition and results of operations.&#160;For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website <u>http://www.amf-france.org</u> or on <u>Innate Pharma&#8217;s website</u><u>, </u>and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.</p>  <p align="justify">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<br ><br ></p>  <p align="justify"><strong><strong>For additional information, please contact:</strong></strong></p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:30%; width:30%; min-width:30%;;text-align: justify ;  vertical-align: middle; vertical-align: top ; "><strong><u>Investors</u></strong><br ><br > <strong>Innate Pharma&#160; </strong><br > Tel.: +33 (0)4 30 30 30 30<br > <u>investors@innate-pharma.com</u><br ><br > <u><strong>Bpifrance</strong></u><br > Nathalie Police<br > Tel.: +33 (0)1 45 95 26<br > <u>Nathalie.police@bpifrance.fr</u><br ><br > <strong><u>Secr&#233;tariat g&#233;n&#233;ral pour l&#8217;investissement</u></strong><br > Tel.: +33 (0)1 42 75 64 58<br > <u>presse.sgpi@pm.gouv.fr</u> <strong>&#160;</strong></td><td style="max-width:70%; width:70%; min-width:70%;;text-align: justify ;  vertical-align: middle; vertical-align: top ; "><strong><u>Media</u></strong><br ><br > <strong>Innate Pharma&#160; </strong><br > Tracy Rossin (Global/US)<br > Tel.: +1 240 801 0076<br > <u>Tracy.Rossin@innate-pharma.com</u><br ><br > <strong>ATCG Press </strong><br > Marie Puvieux (France)<br > Tel.: +33 (0)9 81 87 46 72<br > <u>innate-pharma@atcg-partners.com</u><br ></td></tr></table></p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
